---
schema_version: "secwatch.filing_event.v1"
accession: "0001567264-25-000040"
form_type: "8-K"
ticker: "INTS"
cik: "0001567264"
company_name: "INTENSITY THERAPEUTICS, INC."
filed_at: "2025-05-13T23:59:59+00:00"
generated_at: "2026-05-21T15:53:52.193162+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Intensity Therapeutics pauses Phase 3 sarcoma study enrollment; Q1 net loss $3.3M, cash $0.9M

## Summary
- Paused new site activations and enrollment in Phase 3 INVINCIBLE-3 sarcoma study due to funding constraints; 23 patients enrolled.
- April 2025 public offering raised $2.35M gross ($1.9M net) to prioritize Phase 2 INVINCIBLE-4 breast cancer trial.
- Q1 2025 net loss $3.3M (vs $4.6M Q1 2024); cash and equivalents $0.9M as of March 31, 2025.
- Eight Swiss sites activated in INVINCIBLE-4; EMA authorized study in France with Unicancer.

## SEC filing metadata
- accession: 0001567264-25-000040
- form_type: 8-K
- ticker: INTS
- cik: 0001567264
- company_name: INTENSITY THERAPEUTICS, INC.
- filed_at: 2025-05-13T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1567264/000156726425000040/0001567264-25-000040-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1567264/000156726425000040/intensity-20250513.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001567264-25-000040
- JSON: https://secwatch.observer/filing/0001567264-25-000040.json
- Plain text: https://secwatch.observer/filing/0001567264-25-000040.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.